Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101)

  • Details

ClinicalTrials.gov ID: NCT04913337
Diagnosis Type: Lung Cancer
USOR Number: 22245

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101)

  • Details

ClinicalTrials.gov ID: NCT04913337
Diagnosis Type: Lung Cancer
USOR Number: 22245

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101)

  • Details

ClinicalTrials.gov ID: NCT04913337
Diagnosis Type: Lung Cancer
USOR Number: 22245

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Compass Oncology - Vancouver

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Compass Oncology - Portland

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Compass Oncology - Tigard

IMGN853-0421: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

  • Details

ClinicalTrials.gov ID: NCT05445778
Diagnosis Type: Peritoneal Cancer
USOR Number: 22201

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Tigard

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page
1 2 3 4 … 13

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.